Sign in or register to see full information and data.

Studies / CAVD 314


Study information

Grant Affiliation:Weiss: Protection by Neutralizing Antibodies
Strategy:Combo: DNA, protein & VLP vaccines
Study Type:Pre-Clinical Non-NHP
Stage:Assays Completed
Study Start Date:2011-04-12
Study Made Public:2011-08-08


The induction of neutralising antibodies to HIV env proteins by modifications to gp41.


CAVD 314 is a preclinical rabbit study investigating several prime-boost regimens in which HIV env gp160 protein and modified gp41 constructs were boosted with virus-like particles containing the corresponding modified gp41 proteins.


CFA IFA CN54env-gp140 CTM-2F5 CTM CTM-H3 CTM-GCN-gp41 ZM96 GCN-gp41 FD VLP-GCN-gp41 CTM VLP-H3 CTM VLP-gp41 CTM

Integrated data

No integrated data is available for this study.

Non-integrated data

No non-integrated data is available for this study.